ADOLESCENT AND PARENT EXPERIENCES WITH LONG-ACTING INJECTABLES IN THE MOCHA STUDY
The ongoing More Options for Children and Adolescents Study (MOCHA; Clinicaltrials.gov NCT03497676) is the first to examine use of long-acting injectable (LA) antiretrovirals (ARV) (cabotegravir [CAB-LA] and rilpivirine [RPV-LA]) in adolescents, 12 to